TNFAIP8 overexpression: clinical relevance to esophageal squamous cell carcinoma.

Department of General Surgical Science (Surgery 1), Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan.
Annals of Surgical Oncology (Impact Factor: 4.12). 10/2011; 19 Suppl 3:S589-96. DOI: 10.1245/s10434-011-2097-1
Source: PubMed

ABSTRACT Tumor necrosis factor alpha-induced protein 8 (TNFAIP8) is a suppressor of TNF-α mediated apoptosis, and its expression is induced by NF-κB activation. TNFAIP8 expression is significantly increased in various cancer cell lines. A correlation between TNFAIP8 overexpression, cancer progression, and poor prognosis has been described in many reports of human solid cancers.
To clarify the functional and clinical significance of the cancer progression-related gene, TNFAIP8, in esophageal squamous cell carcinoma (ESCC), we used immunohistochemistry to demonstrate TNFAIP8 expression in ESCC. Next, TNFAIP8 expression was depleted by using siRNA to examine the function of TNFAIP8 in the proliferation and apoptosis induction of ESCC cell lines.
We detected correlations between TNFAIP8 expression and TNM stage (P < 0.001), tumor depth (P = 0.002), lymph node metastasis (P = 0.013), distant metastasis (P = 0.001), lymphatic invasion (P < 0.001), and venous invasion (P < 0.001) among the clinicopathological characteristics of ESCC patients, and high TNFAIP8 expression was found in poor survival. TNFAIP8 depletion was significantly associated with apoptosis induction after cisplatin administration and reduced proliferation.
Our results suggest that TNFAIP8 might be an effective therapeutic target for ESCC in the future.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Tumor necrosis factor alpha-induced protein 8 (TNFAIP8) has been recently documented in various malignancies, but its role in non-small cell lung cancer (NSCLC) remains uncertain. In the current study, we investigated the level of TNFAIP8 in NSCLC tissues, adjacent noncancerous lung tissues, healthy lung tissues, CD4+ T cells, and CD8+ T cells by real-time reverse transcription PCR (RT-PCR) and Western blot analysis. Results revealed that the mRNA level of TNFAIP8 was significantly increased in cancer tissue than in healthy lung tissue from donors (p < 0.001). Interestingly, adjacent noncancerous lung tissues also showed higher mRNA level of TNFAIP8 than healthy lung tissue from donors (p < 0.01). Similarly, protein level of TNFAIP8 was elevated in NSCLC tissues and adjacent noncancerous lung tissues. We further analyzed TNFAIP8 expression in CD4+ T cells and CD8+ T cells. Data demonstrated that both mRNA level and protein level were significantly decreased in tumor-infiltrating CD4+ and CD8+ T cells than in peripheral CD4+ and CD8+ T cells. Moreover, patients with advanced stages presented lower protein expression of TNFAIP8 in tumor-infiltrating CD8+ T cells than patients with primary stages (p < 0.05). These results provide evidence that TNFAIP8 plays critical roles in NSCLC and may be used as a therapeutic target for the disease.
    Tumor Biology 10/2013; · 2.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background:Tumour necrosis factor-α-induced protein 8 (TNFAIP8) has been recently documented in various malignancies, but its role in epithelial ovarian cancer (EOC) remains unknown.Methods:Tumour necrosis factor-α-induced protein 8 expression was determined by real-time reverse transcription PCR and western blot analysis. Tumour tissues, consisting of serous, mucinous, endometrioid and clear cell histotypes, from 202 EOC patients (International Federation of Gynecologists and Obstetricians I-IV) who underwent primary cytoreduction were collected. Then, we examined the immunohistochemical expression of TNFAIP8 and evaluated its clinical significances.Results:Tumour necrosis factor-α-induced protein 8 overexpression was significantly associated with high histologic grade (P=0.005), large residual tumour size (P=0.014), recurrence (P=0.024) and response to chemotherapy (P<0.001). Multivariate analysis showed that TNFAIP8 overexpression was independently correlated with the presence of lymph node (odds ratio (OR): 4.129; 95% confidence interval (CI): 1.491-11.435; P=0.006) and intraperitoneal metastasis (OR: 2.209; 95% CI: 1.174-4.156; P=0.014). Moreover, results revealed that the status of TNFAIP8 expression was an independently prognostic factor for both cancer-specific survival (hazard ratio (HR): 1.852; 95% CI: 1.322-2.594; P<0.001) and disease-free survival (HR: 1.724; 95% CI: 1.235-2.407; P=0.001) in patients with EOC.Conclusion:The present data provide evidence that TNFAIP8 predicts EOC metastasis and poor survival, highlighting its potential function as a therapeutic target for EOCs.British Journal of Cancer advance online publication, 27 August 2013; doi:10.1038/bjc.2013.501
    British Journal of Cancer 08/2013; · 5.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Here we correlated tumor necrosis factor-α-induced protein 8 (TNFAIP8) mRNA expression with clinicopathological parameters, and investigated the involvement of TNFAIP8 over-expression in platinum resistance of epithelial ovarian cancer (EOC). The status of TNFAIP8 protein was evaluated by Western blot analysis (n = 25) and immunohistochemistry (n = 134). TNFAIP8 mRNA expression was assessed with real-time polymerase chain reaction in fresh frozen EOC tissues (n = 40). TNFAIP8 over-expression at both mRNA and protein levels in platinum-resistant disease was clearly higher than that in platinum-sensitive disease (P < .05). Platinum resistance was independently correlated with residual tumor size (P = .025), ascites (P = .027) and TNFAIP8 over-expression (P = .003). In particular, TNFAIP8 over-expression was correlated with platinum resistance in EOCs with optimal cytoreduction (P = .001). TNFAIP8 mRNA expression was strongly associated with residual tumor size (P = .019). In conclusion, our findings indicate that TNFAIP8 over-expression is an independent predictor of platinum resistance and may be a potential biomarker for targeted therapy.
    Human pathology 01/2014; · 3.03 Impact Factor